In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Find the latest analyst research, reports, and ratings for Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) at Nasdaq.com.